Jung Julie Kang

Yale University

Papers

1

Total Citations

57

H-Index

1

About

Dr. Jung Julie Kang is a leading voice in the evolving landscape of head and neck oncology, with a primary research focus on treatment deintensification for human papillomavirus (HPV)-associated oropharyngeal cancer. Her most cited work, a 2022 landmark review, synthesizes the consensuses and controversies surrounding de-escalation strategies, addressing the critical need to reduce long-term toxicities from chemoradiation without compromising the excellent prognosis of HPV-positive disease. This paper, with 57 citations, has become a key reference for clinicians and researchers navigating this paradigm shift. Dr. Kang’s contributions are particularly impactful given the rising incidence of HPV-positive oropharyngeal cancer in the United States, where it is now the most common HPV-related malignancy. Her scholarship helps define future directions for personalized, less morbid treatments, positioning her as a pivotal figure in improving quality of life for survivors. Her work is essential reading for anyone interested in the intersection of virology, radiation oncology, and patient-centered care.

Research Focus

Key Achievements

1
H-Index
1
Papers
57
Total Citations
57
Avg Citations/Paper
🏆 Most Cited Paper
Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer
57 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: Yale University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago